Brief: Novo Nordisk To Acquire Akero Therapeutics

Akero Therapeutics

09/10/2025 11:04

Oct 9 (Reuters) - Novo Nordisk NOVOb.CO:

TO ACQUIRE AKERO THERAPEUTICS AND ITS PROMISING PHASE 3 FGF21 ANALOGUE TO EXPAND MASH PORTFOLIO

TO BUY AKERO FOR $4.7 BILLION IN CASH

AKERO'S EFRUXIFERMIN SHOWS SIGNIFICANT FIBROSIS REGRESSION IN PHASE 2

AKERO BOARD APPROVES DEAL, EXPECTED TO CLOSE YEAR-END

DEAL NOT EXPECTED TO IMPACT NOVO NORDISK'S 2025 PROFIT OUTLOOK

2025 FREE CASH FLOW OUTLOOK NEGATIVELY IMPACTED BY $4 BILLION

FOR 2026, ACQUISITION IS EXPECTED TO LEAD TO INCREASED RESEARCH AND DEVELOPMENT T COSTS

NEGATIVE IMPACT ON FY OPERATING PROFIT GROWTH IN 2026 OF AROUND 3%-POINTS

IMPLIED 2025 FREE CASH FLOW OUTLOOK IS THEREFORE 9-19 BILLION DKK DEPENDING ON TIMING OF CLOSING

2026 PROFIT GROWTH IMPACTED BY 3%-POINTS DUE TO RESEARCH AND DEVELOPMENT COSTS

TRANSACTION WILL BE MAINLY DEBT FINANCED

Source text: ID:nGNE7wTg5z

Further company coverage: NOVOb.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))